| Full text | |
| Author(s): |
Ramos, Rodrigo Nalio
[1, 2]
;
Picanco-Castro, Virginia
[3]
;
Oliveira, Theo Gremen M.
[1, 4]
;
Mendrone, Alfredo
[4]
;
De Santis, Gil Cunha
[3]
;
Bonamino, Martin Hernan
[5, 6]
;
Rocha, Vanderson
[1, 2, 4]
Total Authors: 7
|
| Affiliation: | [1] Fac Med Univ Sao Paulo HCFMUSP, Hosp Clin, Lab Invest Med Patogenese & Terapia Dirigida Onco, Sao Paulo, SP - Brazil
[2] Inst DOr Ensino & Pesquisa, Sao Paulo - Brazil
[3] Hosp Clin Fac Med Ribeirao Preto Univ Sao Paulo, Fundacao Hemoctr Ribeirao Preto, Ribeirao Preto, SP - Brazil
[4] Fundacao Pro Sangue Hemoctr Sao Paulo, Sao Paulo - Brazil
[5] Inst Nacl Canc INCA, Div Pesquisa Expt & Translac, Rio De Janeiro, RJ - Brazil
[6] Pesquisa & Colecoes Biol Fundacao Oswaldo Cruz VP, Rio De Janeiro, RJ - Brazil
Total Affiliations: 6
|
| Document type: | Journal article |
| Source: | Hematology, Transfusion and Cell Therapy; v. 43, n. 2, p. S46-S53, NOV 2021. |
| Web of Science Citations: | 0 |
| Abstract | |
Chimeric Antigen Receptor T (CAR-T) cells are certainly an important therapy for patients with relapsed and/or refractory hematologic malignancies. Currently, there are five CAR-T cell products approved by the FDA but several research groups and/or biopharmaceutical companies are encouraged to develop new products based on CAR cells using T or other cell types. Production of CAR cells requires intensive work from the basic, pre-clinical to translational levels, aiming to overcome technical difficulties and failure in the production. At least five key common steps are needed for the manipulation of T-lymphocytes (or other cells), such as: cell type selection, activation, gene delivery, cell expansion and final product formulation. However, reproducible manufacturing of high-quality clinical-grade CAR cell products is still required to apply this technology to a greater number of patients. This chapter will discuss the present and future development of new CAR designs that are safer and more effective to improve this therapy, achieving more selective killing of malignant cells and less toxicity to be applied in the clinical setting. (C) 2021 Published by Elsevier Espana, S.L.U. on behalf of Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular. (AU) | |
| FAPESP's process: | 19/25309-0 - Off-the-shelf engineered NK cells for the treatment of Leukemia and Lymphoma treatment |
| Grantee: | Virginia Picanço e Castro |
| Support Opportunities: | Regular Research Grants |
| FAPESP's process: | 13/08135-2 - CTC - Center for Cell-Based Therapy |
| Grantee: | Dimas Tadeu Covas |
| Support Opportunities: | Research Grants - Research, Innovation and Dissemination Centers - RIDC |